Below, you will find a list of sessions focused on anti-obesity medications, specifically GLP-1 agonists that we are eagerly looking forward to at #ObesityMedicine2025
This second wave will be an important European proving ground for off-patent manufacturers before the third and largest wave of markets opens up, namely the US and most of Europe
Earlier this week, The Lancet published the results of a study on an oral GLP-1 medication, orforglipron, that showed promising results: tests in 10 countries found that it outperformed a placebo
Commentary on: Aesthetic Surgery Journal articles on injectable weight loss medications and their role in plastic surgery
Tong, G., Peng, T., Chen, Y., Sha, L., Dai, H., Xiang, Y., Zou, Z., He, H., & Wang, S